Patents by Inventor Jocelyn Dupuis

Jocelyn Dupuis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11844771
    Abstract: Disclosed are methods of treating Acute Respiratory Distress Syndrome using colchicine, e.g., by administering colchicine to a subject in need thereof.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: December 19, 2023
    Assignee: INSTITUT DE CARDIOLOGIE DE MONTREAL
    Inventors: Jean-Claude Tardif, Jocelyn Dupuis
  • Publication number: 20220362181
    Abstract: Disclosed are methods of treating Acute Respiratory Distress Syndrome using colchicine, e.g., by administering colchicine to a subject in need thereof.
    Type: Application
    Filed: April 6, 2022
    Publication date: November 17, 2022
    Inventors: Jean-Claude TARDIF, Jocelyn DUPUIS
  • Publication number: 20150246145
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Application
    Filed: May 19, 2015
    Publication date: September 3, 2015
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: 9062123
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: June 23, 2015
    Assignee: PLUMOSCIENCE INC.
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: 8703098
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: April 22, 2014
    Assignee: Institut de Cardiologie de Montreal
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: 8475764
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: July 2, 2013
    Assignee: Institut de Cardiologie de Montreal
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Publication number: 20120082619
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Application
    Filed: July 7, 2011
    Publication date: April 5, 2012
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Publication number: 20090028790
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Application
    Filed: May 12, 2008
    Publication date: January 29, 2009
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Publication number: 20080274050
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
    Type: Application
    Filed: May 24, 2005
    Publication date: November 6, 2008
    Applicant: INSTITUT DE CARDIOLOGIE DE MONTRÉAL
    Inventors: Jocelyn Dupuis, Alain Fournier